Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality
about
Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens.Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysisHealthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents.Healthcare costs attributable to the treatment of patients with spinal metastases: a cohort study with up to 8 years follow-up.Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study.Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in EuropeEffect of a Nurse-Led Psychoeducational Intervention on Healthcare Service Utilization Among Adults With Advanced Cancer.Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system.Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer.'Suspect molecular signature' in blood as the indicator of undiagnosed breast cancer, cancer risk and targeted preventionSequential Metastatic Breast Cancer Chemotherapy: Should the Median be the Message?Relevance of health economics in breast cancer treatment: integration of economics in the management of breast cancer at the clinic levelEarly integration of palliative care services with standard oncology care for patients with advanced cancer.Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population.Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis.Degradable poly(apigenin) polymer inhibits tumor cell adhesion to vascular endothelial cells.
P2860
Q33718051-379BA562-B686-4D93-9326-811DBD20E41CQ33721983-AE3C58AA-E41F-4DBF-881D-570C598260E7Q34080274-00A2F2DE-1ED3-4BB2-8577-D737B1CE19AFQ35584044-5943DBF1-A22A-42FD-B291-B3EC37786F97Q35736115-3332BBA6-F212-4340-9112-9B7CA35F4F80Q35820168-D8074ECD-B54D-4ED0-A839-8BB06635D9C6Q35879797-E2F47DB0-A77B-4EAA-8D8C-A626F42E1E9EQ37338289-A36BC0A3-2203-4B24-9596-597EFB647934Q37350619-4D7643E6-FECA-4E9B-8828-A46C8194C1DBQ37356789-233B86E7-AFD0-4B40-985E-398E703D22CEQ37385471-6086F430-F34D-43F6-9F6F-2186A6FFB025Q37677710-214D0ACC-22D9-40C2-8E32-0C0DA434862BQ38121761-FF28EA5B-70C6-41C9-96E7-28A715165F73Q38162883-36E7DF24-D15B-4AE3-AAC4-F1D64F2367C0Q39742304-4D0C2025-F41A-4626-846D-35A0457B0D44Q48357233-88DF339B-AC05-43DC-A629-54537570C25EQ50760615-A5F282F0-BBE6-4DFB-AEC3-4D49719F87A0Q51818359-D5809AAD-7E87-4516-8766-B283E9224A9F
P2860
Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Healthcare costs in women with ...... r principal treatment modality
@ast
Healthcare costs in women with ...... r principal treatment modality
@en
type
label
Healthcare costs in women with ...... r principal treatment modality
@ast
Healthcare costs in women with ...... r principal treatment modality
@en
prefLabel
Healthcare costs in women with ...... r principal treatment modality
@ast
Healthcare costs in women with ...... r principal treatment modality
@en
P2093
P2860
P356
P1433
P1476
Healthcare costs in women with ...... r principal treatment modality
@en
P2093
Andrew Glass
Derek Weycker
Gerry Oster
Montserrat Vera-Llonch
Rohit Borker
P2860
P2888
P356
10.1186/1471-2407-11-250
P407
P577
2011-06-15T00:00:00Z
P5875
P6179
1003146053